Literature DB >> 11544947

[Malignant atrophic papulosis (Köhlmeier-Degos): diagnosis, therapy and course].

C Vicktor1, U Schultz-Ehrenburg.   

Abstract

A 71-year-old male patient presented with malignant atrophic papulosis (Köhlmeier-Degos disease). He developed multiple distinctive cutaneous lesions. The histopathological findings showed an obliterated arteriole with a wedge-shaped area of ulcerated and necrobiotic dermis. Laboratory tests were within normal limits or not specific. Although the involvement of the gastrointestinal tract and other organs has been noted in approximately 60% of the reported cases, in this patient so far the skin seems to be the only involved site. There is no proven effective therapy for Köhlmeier-Degos disease. In our case treatment with pentoxifylline and aspirin led to healing of all skin lesions within 3 months. One year after beginning treatment, the patient showed neither new cutaneous lesions, nor any signs of systemic involvement. The combination of pentoxifylline and aspirin should be considered when planning treatment strategies for malignant atrophic papulosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544947     DOI: 10.1007/s001050170092

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  3 in total

1.  Degos disease - malignant atrophic papulosis or cutaneointestinal lethal syndrome: rarity of the disease.

Authors:  Eduardo Pirolla; Felipe Fregni; Irene K Miura; Antonio Carlos Misiara; Fernando Almeida; Esdras Zanoni
Journal:  Clin Exp Gastroenterol       Date:  2015-04-16

2.  Degos Disease (Malignant Atrophic Papulosis) With Granular IgM on Direct Immunofluorescence.

Authors:  Tatsiana Pukhalskaya; Julia Stiegler; Glynis Scott; Christopher T Richardson; Bruce Smoller
Journal:  Cureus       Date:  2021-01-13

Review 3.  Malignant atrophic papulosis (Köhlmeier-Degos disease) - a review.

Authors:  Athanasios Theodoridis; Evgenia Makrantonaki; Christos C Zouboulis
Journal:  Orphanet J Rare Dis       Date:  2013-01-14       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.